NO995077D0 - Fremgangsmåte ved anvendelse av cyklooksygenase-2 inhibitorer i forhindringen av kardiovaskulaere forstyrrelser - Google Patents
Fremgangsmåte ved anvendelse av cyklooksygenase-2 inhibitorer i forhindringen av kardiovaskulaere forstyrrelserInfo
- Publication number
- NO995077D0 NO995077D0 NO995077A NO995077A NO995077D0 NO 995077 D0 NO995077 D0 NO 995077D0 NO 995077 A NO995077 A NO 995077A NO 995077 A NO995077 A NO 995077A NO 995077 D0 NO995077 D0 NO 995077D0
- Authority
- NO
- Norway
- Prior art keywords
- cyclooxygenase
- inhibitors
- prevention
- cardiovascular disorders
- cardiovascular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4462697P | 1997-04-18 | 1997-04-18 | |
PCT/US1998/007318 WO1998047509A1 (en) | 1997-04-18 | 1998-04-16 | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
NO995077D0 true NO995077D0 (no) | 1999-10-18 |
NO995077L NO995077L (no) | 1999-12-17 |
Family
ID=21933403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO995077A NO995077L (no) | 1997-04-18 | 1999-10-18 | Fremgangsmåte ved anvendelse av cyklooksygenase-2 inhibitorer |
Country Status (26)
Country | Link |
---|---|
EP (2) | EP0979077A1 (no) |
JP (1) | JP2001527542A (no) |
KR (1) | KR20010006443A (no) |
CN (1) | CN1253502A (no) |
AP (1) | AP9901674A0 (no) |
AU (1) | AU745797B2 (no) |
BG (1) | BG103803A (no) |
BR (1) | BR9808932A (no) |
CA (1) | CA2286673A1 (no) |
EA (1) | EA199900837A1 (no) |
EE (2) | EE9900517A (no) |
GE (1) | GEP20022812B (no) |
HU (1) | HUP0001777A3 (no) |
ID (1) | ID23687A (no) |
IL (1) | IL132163A0 (no) |
IS (1) | IS5203A (no) |
NO (1) | NO995077L (no) |
NZ (1) | NZ500141A (no) |
OA (1) | OA11261A (no) |
PL (1) | PL337098A1 (no) |
SK (1) | SK138799A3 (no) |
TR (1) | TR199902545T2 (no) |
UA (1) | UA68348C2 (no) |
WO (1) | WO1998047509A1 (no) |
YU (1) | YU53899A (no) |
ZA (1) | ZA983249B (no) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448235B1 (en) | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
US6710033B1 (en) | 1996-08-14 | 2004-03-23 | Vanderbilt University | Methods and treatment of multiple sclerosis |
US7030152B1 (en) * | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
EP1767223A1 (en) * | 1999-08-31 | 2007-03-28 | The Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
EP1520590A1 (en) * | 1999-08-31 | 2005-04-06 | The Brigham and Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
JP2003508453A (ja) * | 1999-08-31 | 2003-03-04 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | アテローム性動脈硬化疾患の予防における診断的ツールとしての全身性炎症マーカー |
KR20040023660A (ko) * | 2001-07-19 | 2004-03-18 | 파마시아 코포레이션 | 알도스테론 수용체 길항제 및 hmg coa 환원효소억제제의 병용물 |
EP1434782A2 (en) | 2001-10-01 | 2004-07-07 | University of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
KR100686537B1 (ko) * | 2001-12-28 | 2007-02-27 | 씨제이 주식회사 | 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체 |
WO2003074101A1 (en) * | 2002-02-28 | 2003-09-12 | Eli Lilly And Company | Method of treating atherosclerosis and hypercholesterolemia |
AU2003262831A1 (en) | 2002-08-23 | 2004-03-11 | Rigel Pharmaceuticals, Inc. | Pyridyl substituted heterocycles useful for treating or preventing hcv infection |
EP1400243A1 (en) * | 2002-09-19 | 2004-03-24 | Tanabe Seiyaku Co., Ltd. | Calcium-activated K channel activator |
JP2004189711A (ja) * | 2002-12-11 | 2004-07-08 | Raul Altman | 急性冠動脈症候群および関連病態の治療のための抗血小板薬と組合せたメロキシカムの使用 |
EP1590336B1 (en) | 2003-01-27 | 2010-12-01 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
WO2004099165A2 (en) | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Heterocyclic compounds and hydro isomers thereof |
WO2004099164A1 (en) | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection |
PL1534305T3 (pl) | 2003-05-07 | 2007-03-30 | Osteologix As | Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie |
US7220745B2 (en) | 2003-05-15 | 2007-05-22 | Rigel Pharmaceuticals | Heterocyclic compounds useful to treat HCV |
WO2005049065A2 (en) | 2003-11-19 | 2005-06-02 | Rigel Pharmaceuticals, Inc. | Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections |
US7514434B2 (en) | 2004-02-23 | 2009-04-07 | Rigel Pharmaceuticals, Inc. | Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof |
JP4108739B2 (ja) | 2004-06-04 | 2008-06-25 | メルク エンド カムパニー インコーポレーテッド | ピラゾール誘導体、かかる化合物を含む組成物及び使用方法 |
US7442687B2 (en) | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
AU2005267706B2 (en) | 2004-08-02 | 2011-12-08 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
US7576069B2 (en) | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
WO2007027230A2 (en) | 2005-05-02 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses |
US20070037797A1 (en) * | 2005-08-15 | 2007-02-15 | Hellstrom Harold R | Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events |
US8404275B2 (en) | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
CA2756870A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
US9226891B2 (en) | 2011-10-28 | 2016-01-05 | Vitalis Llc | Anti-flush compositions |
CN115671097B (zh) * | 2022-08-23 | 2024-02-13 | 上海交通大学医学院附属第九人民医院 | 用于防治动脉粥样硬化及斑块不稳定性的化合物及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3103372A1 (de) * | 1981-01-27 | 1982-09-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue indanyl-derivate, ihre herstellung und verwendung |
JP2893903B2 (ja) * | 1990-09-12 | 1999-05-24 | 藤沢薬品工業株式会社 | 虚血―再灌流障害予防、治療剤 |
JP3086312B2 (ja) * | 1991-10-28 | 2000-09-11 | 富山化学工業株式会社 | インターロイキン6の産生抑制剤並びにその産生抑制作用が有効な疾患の治療・予防剤 |
US5380738A (en) * | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
US5344991A (en) * | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
NZ536355A (en) * | 1993-11-30 | 2006-08-31 | Searle & Co | Method of treating inflammation using substituted pyrazolyl benzenesulfonamides |
US5434178A (en) * | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
US5393790A (en) * | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
EP1125932A3 (en) * | 1994-07-27 | 2001-08-29 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
WO1996025405A1 (en) * | 1995-02-13 | 1996-08-22 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
CA2221692A1 (en) * | 1995-05-19 | 1996-11-21 | G.D. Searle & Co. | Substituted oxazoles for the treatment of inflammation |
US5643933A (en) * | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
AU5886296A (en) * | 1995-06-02 | 1996-12-18 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors |
CA2224563A1 (en) * | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations |
CA2224517A1 (en) * | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
US5700816A (en) * | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
GB9520584D0 (en) * | 1995-10-09 | 1995-12-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
-
1998
- 1998-04-16 EE EEP199900517A patent/EE9900517A/xx unknown
- 1998-04-16 CA CA002286673A patent/CA2286673A1/en not_active Abandoned
- 1998-04-16 UA UA99105689A patent/UA68348C2/uk unknown
- 1998-04-16 BR BR9808932-3A patent/BR9808932A/pt not_active Application Discontinuation
- 1998-04-16 EP EP98922028A patent/EP0979077A1/en not_active Withdrawn
- 1998-04-16 EP EP04023890A patent/EP1498140A2/en not_active Withdrawn
- 1998-04-16 WO PCT/US1998/007318 patent/WO1998047509A1/en not_active Application Discontinuation
- 1998-04-16 JP JP54611398A patent/JP2001527542A/ja not_active Withdrawn
- 1998-04-16 EE EEP200300169A patent/EE200300169A/xx unknown
- 1998-04-16 KR KR1019997009533A patent/KR20010006443A/ko active Search and Examination
- 1998-04-16 ID IDW991219A patent/ID23687A/id unknown
- 1998-04-16 AP APAP/P/1999/001674A patent/AP9901674A0/en unknown
- 1998-04-16 CN CN98804252A patent/CN1253502A/zh active Pending
- 1998-04-16 HU HU0001777A patent/HUP0001777A3/hu unknown
- 1998-04-16 PL PL98337098A patent/PL337098A1/xx unknown
- 1998-04-16 EA EA199900837A patent/EA199900837A1/ru unknown
- 1998-04-16 GE GEAP19985037A patent/GEP20022812B/en unknown
- 1998-04-16 TR TR1999/02545T patent/TR199902545T2/xx unknown
- 1998-04-16 NZ NZ500141A patent/NZ500141A/en unknown
- 1998-04-16 AU AU74662/98A patent/AU745797B2/en not_active Ceased
- 1998-04-16 IL IL13216398A patent/IL132163A0/xx not_active IP Right Cessation
- 1998-04-16 SK SK1387-99A patent/SK138799A3/sk unknown
- 1998-04-16 YU YU53899A patent/YU53899A/sh unknown
- 1998-04-17 ZA ZA983249A patent/ZA983249B/xx unknown
-
1999
- 1999-09-30 IS IS5203A patent/IS5203A/is unknown
- 1999-10-13 BG BG103803A patent/BG103803A/bg unknown
- 1999-10-18 OA OA9900228A patent/OA11261A/en unknown
- 1999-10-18 NO NO995077A patent/NO995077L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GEP20022812B (en) | 2002-10-25 |
IL132163A0 (en) | 2001-03-19 |
EE9900517A (et) | 2000-06-15 |
EP0979077A1 (en) | 2000-02-16 |
EA199900837A1 (ru) | 2000-10-30 |
HUP0001777A2 (hu) | 2001-05-28 |
SK138799A3 (en) | 2001-01-18 |
UA68348C2 (en) | 2004-08-16 |
JP2001527542A (ja) | 2001-12-25 |
IS5203A (is) | 1999-09-30 |
BR9808932A (pt) | 2000-08-01 |
EE200300169A (et) | 2003-06-16 |
HUP0001777A3 (en) | 2001-07-30 |
AP9901674A0 (en) | 1999-12-31 |
CA2286673A1 (en) | 1998-10-29 |
PL337098A1 (en) | 2000-07-31 |
AU7466298A (en) | 1998-11-13 |
ZA983249B (en) | 1999-04-19 |
OA11261A (en) | 2003-07-24 |
BG103803A (bg) | 2000-05-31 |
EP1498140A2 (en) | 2005-01-19 |
NO995077L (no) | 1999-12-17 |
TR199902545T2 (xx) | 2000-01-21 |
ID23687A (id) | 2000-05-11 |
WO1998047509A1 (en) | 1998-10-29 |
NZ500141A (en) | 2002-05-31 |
KR20010006443A (ko) | 2001-01-26 |
YU53899A (sh) | 2002-10-18 |
AU745797B2 (en) | 2002-03-28 |
CN1253502A (zh) | 2000-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO995077D0 (no) | Fremgangsmåte ved anvendelse av cyklooksygenase-2 inhibitorer i forhindringen av kardiovaskulaere forstyrrelser | |
ATE383769T1 (de) | Inhibitoren des transkriptionsfaktors nf-kappa b | |
ID19198A (id) | Inhibitor metaloprotease heterosiklik | |
NO20001098L (no) | Teknikk for sikre nett-transaksjoner | |
NO20012916L (no) | Sammensetninger og fremgangsmåter for behandling av anorektale forstyrrelser | |
ID18416A (id) | Inhibitor metaloprotease diheterosiklik | |
NO990296D0 (no) | HPPD-genet og inhibitorer | |
DK0916390T3 (da) | Fremgangsmåde ved ejektion af væske og indretning til udøvelse af fremgangsmåden | |
NO983979L (no) | FremgangsmÕte ved nedsettelse av det totale syretall i rÕolje | |
NO983957D0 (no) | Fremgangsmåte ved sammenföyning av tofase rustfritt stål | |
NO20001412D0 (no) | Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser | |
NO992309L (no) | FremgangsmÕte for anvendelse av cyklooksygenase-2 inhibitorer som anti-angiogene midler | |
FI962499A0 (fi) | Herbisidien tehon parantaminen | |
NO923072D0 (no) | Korrosjonsinhibitor til bruk ved oljeutvinning og framgangsmaate for framstilling av samme | |
NO990503D0 (no) | St°tfanger og fremgangsmÕte ved fremstilling av samme | |
NO20015896D0 (no) | Fremgangsmåte for å belegge partikler og partikler produsert ved denne | |
NO990792D0 (no) | FremgangsmÕte for inhibering av ekspresjonen av FAS | |
NO20001758D0 (no) | Fremgangsmåter og blandinger for behandling av leddgikt | |
NO993034D0 (no) | Bjelke og fremgangsmÕte ved fremstilling av samme | |
NO993102D0 (no) | Chipkort og fremgangsmÕte ved anvendelse av chipkortet | |
NO962940D0 (no) | Fremgangsmåte ved hydroisomerisering | |
ID17941A (id) | Metode penerapan komposisi pembuat marka jalan | |
NO990614L (no) | Fremgangsmåte ved sammenföyning av metallmateriale | |
NO20002436D0 (no) | Sammensetning og fremgangsmÕte for fjerning av fosfationinnholdet i vann | |
SI0971714T1 (en) | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |